Related Experiment Video

Updated: Jun 8, 2026

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

How Darwinian models inform therapeutic failure initiated by clonal heterogeneity in cancer medicine

M Gerlinger1, C Swanton

  • 1Translational Cancer Therapeutics Laboratory, Cancer Research UK London Research Institute, 44 Lincoln's Inn Fields, London WC2A 3LY, UK.

British Journal of Cancer
|September 30, 2010
PubMed

Insights

Cancer drug resistance evolves through Darwinian principles, accelerated by genomic instability and tumor heterogeneity. Understanding these evolutionary mechanisms is key to developing new therapeutic strategies.

Area of Science:

  • Oncology
  • Evolutionary Biology
  • Genetics

Background:

  • Carcinogenesis involves cellular evolution, leading to cancer hallmarks.
  • Evolutionary adaptation is a proposed mechanism for developing cancer drug resistance.
  • Darwinian models explain how cancer cells acquire advantageous traits.

Purpose of the Study:

  • To review evidence for the evolution of resistance to anti-cancer drugs.
  • To highlight factors accelerating drug resistance.
  • To discuss clinical implications and prevention strategies.

Main Methods:

  • Review of existing literature on cancer drug resistance.
  • Analysis of Darwinian models applied to cancer evolution.
  • Discussion of genomic instability and intra-tumor heterogeneity.

Main Results:

  • Genomic instability and high intra-tumor genetic heterogeneity accelerate drug resistance.
  • Evolutionary adaptation drives resistance to cytotoxic and targeted therapies.
  • Clinical strategies are needed to counter resistance evolution.

Conclusions:

  • Understanding cancer evolution is crucial for overcoming drug resistance.
  • Targeting genetic heterogeneity may prevent resistance.
  • New technologies and serial biopsies are vital for future research.

More Related Videos

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer07:45

Orthotopic Transplantation of Breast Tumors as Preclinical Models for Breast Cancer

Published on: May 18, 2020

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models05:33

Unveiling Therapeutic Opportunities with Melanoma Patient-derived Organoid Models

Published on: September 6, 2024

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Cancer02:18

Cancer

Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Cancer Stem Cells and Tumor Maintenance02:40

Cancer Stem Cells and Tumor Maintenance

Early diagnosis and treatment can often cure cancer. However, even with treatment, residual cells called cancer stem cells (CSC) might remain, often causing tumor recurrence. These cancer stem cells possess the potential for self-renewal and multi-lineage differentiation and are often responsible for the therapeutic resistance displayed in most cancers.
Cancer stem cells are thought to originate from tissue-specific normal stem cells or progenitor cells. The normal stem cells usually reside in...
Cancers Originate from Somatic Mutations in a Single Cell02:21

Cancers Originate from Somatic Mutations in a Single Cell

Cancer arises from mutations in the critical genes that allow healthy cells to escape cell cycle regulation and acquire the ability to proliferate indefinitely. Though originating from a single mutation event in one of the originator cells, cancer progresses when the mutant cell lines continue to gain more and more mutations, and finally, become malignant. For example, chronic myelogenous leukemia (CML) develops initially as a non-lethal increase in white blood cells, which progressively...
Adaptive Mechanisms in Cancer Cells02:53

Adaptive Mechanisms in Cancer Cells

Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...